Member Info for RayPointer

The other aspect of SCIB1 that should not be forgotten, is that it has previously shown a strong memory effect.

If you recall in the original SCIB1 trial, long after SCIB1 dosing had finished, the majority of patient were still alive after 5 years. This is in addition to the results we have seen today, and is something that is not provided by CPIs alone.

WTP, try this

https://www.lsegissuerservices.com/spark/ScancellHoldings/events/ab1023d6-85fa-4125-be9f-527b5166fd7d

Let's also not forget Covidity in all this.

With more evidence that Immunobody works well, it may provoke more interest in Covidity.

The main clue has always been the results of the first SCIB1 trial

What price immunobody now?

It could go ☝

Sorry to be dogmatic, but what pawsible connection has this company with Scancell?

"Given the monotherapy disease control rate in advanced "UNTREATABLE" ovarian cancer is 44%, well above the Response rate of interest, then I would love to understand how you have decided it is not commercial?"

Good point konar.

It's just that Lindy was talking about persuading the regulators to agree to a cohort for Modi1 + CPIs for ovarian.

https://www.lse.co.uk/rns/SCLP/pipeline-strategy-and-business-update-tx5o1w5rf55w1b6.html

"I am pleased to see that Modi-1 is having an effect on disease control in ovarian cancer in these very heavily pre-treated patients, although we believe the true value of our vaccine is probably in combination with checkpoint inhibitors."

"The number of patients who have experienced long periods of stable disease following monotherapy with Modi-1 is encouraging in this difficult to treat cancer and the Company believes that combination therapy with checkpoint inhibitors, which are not currently approved for the treatment of ovarian cancer, could further improve outcomes for this patient group. Evaluation of Modi-1 plus checkpoint inhibitors in other tumour types in the ongoing Phase 1/2 study, will provide supporting data for this proposed combination use."

But yes, without doubt, so far the ovarian cohort looks to be showing the best results of the 4 monotherapies.

I agree with crumbs in that, Modi1 as a monotherapy, is not looking like a commercial product.

The focus then shifts to the other (non monotherapy) cohorts.

I'm not sure there will be enough data to start reporting on these cohorts at present.

The SCIB1 trial data may, hopefully, be the surprise package.

Hi LL

Lindy has always had a great interest in pancreatic cancer and I believe it is what started her off in studying glycans as targets.

https://www.pcrf.org.uk/research-project/2012-lindy-durrant/

https://vimeo.com/20073384

All the best to your relative

Nah, sub 6p by EOM 🤣

You can't buy or sell solely on the results of one patient.

I do feel very sorry for Trish, especially since she was not allowed to switch to the +CI cohort.

Give the guy a chance, he's been working hard to gain his PhD 🤣

Always good to have a pint before sex

We don't shoot the messenger these days, at least most countries don't.

There is still a lot to play for with Modi1 and, logically Modi1 + CPIs should give better results than the monotherapies. All we know at present is that it appears to be having an affect in 1 patient but not so far in another.

Modi1 with or without CPIs before surgery should logically give even better outcomes.

Trish's result are a puzzle with over 50% reduction quite quickly, and then it seemed to stop working. Perhaps, as Bojo said, there may have been a residual affect from the CPIs she was on previously.

Await the more informed results, or not if you are so inclined. As crumbs says, it is your choice.

I think I will go for spicy Italian

https://www.fastfoodmenuprices.com/uk/subway-menu-prices-uk

I hadn't realised that Scancell had diversified into the manure business 😀

It could be your employer 😂

They will do well to beat their record number of posters at a conference 😀

https://www.scancell.co.uk/Data/Sites/1/media/publications/rns/scancell-cri-cimt-eati-aacr-international-cancer-conference-september-2019.pdf

Nice find Johnny but why on earth did Scancell not RNS this collaboration?

Perhaps they will tomorrow.

Will the pivot be clockwise or anti-clockwise? 😀